S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
66,000% upside on tiny biotech? (Ad)
MarketBeat Week in Review – 9/18 - 9/22
The federal government is headed into a shutdown. What does it mean, who's hit and what's next?
66,000% upside on tiny biotech? (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Auto workers still have room to expand their strike against car makers. But they also face risks
66,000% upside on tiny biotech? (Ad)
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
66,000% upside on tiny biotech? (Ad)
MarketBeat Week in Review – 9/18 - 9/22
The federal government is headed into a shutdown. What does it mean, who's hit and what's next?
66,000% upside on tiny biotech? (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Auto workers still have room to expand their strike against car makers. But they also face risks
66,000% upside on tiny biotech? (Ad)
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
66,000% upside on tiny biotech? (Ad)
MarketBeat Week in Review – 9/18 - 9/22
The federal government is headed into a shutdown. What does it mean, who's hit and what's next?
66,000% upside on tiny biotech? (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Auto workers still have room to expand their strike against car makers. But they also face risks
66,000% upside on tiny biotech? (Ad)
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
66,000% upside on tiny biotech? (Ad)
MarketBeat Week in Review – 9/18 - 9/22
The federal government is headed into a shutdown. What does it mean, who's hit and what's next?
66,000% upside on tiny biotech? (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Auto workers still have room to expand their strike against car makers. But they also face risks
66,000% upside on tiny biotech? (Ad)
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
NASDAQ:KDNY

Chinook Therapeutics (KDNY) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$40.29
$40.51
50-Day Range
$38.66
$40.39
52-Week Range
$18.34
$40.51
Volume
4.92 million shs
Average Volume
1.19 million shs
Market Capitalization
$2.90 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$38.14

Chinook Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.23 Rating Score
Upside/​Downside
5.6% Downside
$38.14 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$45,587 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.30) to ($3.50) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.83 out of 5 stars

Medical Sector

961st out of 967 stocks

Biotechnology Industry

24th out of 26 stocks


KDNY stock logo

About Chinook Therapeutics (NASDAQ:KDNY) Stock

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington. As of August 11, 2023, Chinook Therapeutics, Inc. operates as a subsidiary of Novartis AG.


KDNY Stock News Headlines

Chinook Therapeutics, Inc. (KDNY)
This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
Expert Ratings for Chinook Therapeutics
Chinook Therapeutics (NASDAQ: KDNY)
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"
The Washington Post Reports it's: "A revolution in warfare." The Sunday Times Reports it's: "a revolutionary power." Early investors can reap 5,633% gains as England, Germany, Japan and Australia rush to sign contracts. Get the name of the stock here >>>
Why Are Chinook Therapeutics Shares Trading Higher Today
What 6 Analyst Ratings Have To Say About Chinook Therapeutics
Novartis Buys Chinook: M&A To Drive Future Growth
Chinook Shareholder Action Reminder
Chinook Shareholder Notice
Chinook Investor Alert
See More Headlines
Receive KDNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chinook Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KDNY Company Calendar

Last Earnings
8/07/2023
Today
9/23/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KDNY
Fax
N/A
Employees
214
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$38.14
High Stock Price Forecast
$43.00
Low Stock Price Forecast
$32.00
Forecasted Upside/Downside
-5.6%
Consensus Rating
Hold
Rating Score (0-4)
2.23
Research Coverage
13 Analysts

Profitability

Net Income
$-187,870,000.00
Net Margins
-4,199.93%
Pretax Margin
-4,115.56%

Debt

Sales & Book Value

Annual Sales
$6.13 million
Book Value
$6.91 per share

Miscellaneous

Free Float
59,749,000
Market Cap
$2.90 billion
Optionable
Optionable
Beta
0.34
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Eric L. Dobmeier J.D. (Age 54)
    Pres, CEO & Director
    Comp: $972.19k
  • Mr. Tom FrohlichMr. Tom Frohlich (Age 47)
    Chief Operating Officer
    Comp: $627.44k
  • Mr. Andrew James King D.V.M.Mr. Andrew James King D.V.M. (Age 43)
    Ph.D., Chief Scientific Officer
    Comp: $651.48k
  • Mr. Eric H. Bjerkholt M.B.A. (Age 63)
    Chief Financial Officer
  • Ms. Sukhi Thethy
    Sr. VP of Fin. & Accounting
  • Ms. Noopur Batsha Liffick
    Sr. VP of Investor Relations & Corp. Communications
  • Mr. Kirk D. Schumacher J.D.
    Sr. VP & Gen. Counsel
  • Ms. Jodi Jamieson
    Sr. VP of HR
  • Dr. Alan Glicklich M.D. (Age 60)
    Exec. Officer
  • Ms. Delphine Imbert Ph.D.
    Sr. VP of CMC & Technical Operations













KDNY Stock - Frequently Asked Questions

Should I buy or sell Chinook Therapeutics stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Chinook Therapeutics in the last year. There are currently 10 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" KDNY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KDNY, but not buy additional shares or sell existing shares.
View KDNY analyst ratings
or view top-rated stocks.

What is Chinook Therapeutics' stock price forecast for 2023?

13 brokers have issued twelve-month price objectives for Chinook Therapeutics' stock. Their KDNY share price forecasts range from $32.00 to $43.00. On average, they predict the company's stock price to reach $38.14 in the next twelve months. This suggests that the stock has a possible downside of 5.6%.
View analysts price targets for KDNY
or view top-rated stocks among Wall Street analysts.

When is Chinook Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our KDNY earnings forecast
.

How were Chinook Therapeutics' earnings last quarter?

Chinook Therapeutics, Inc. (NASDAQ:KDNY) released its earnings results on Monday, August, 7th. The company reported ($0.94) earnings per share for the quarter, missing analysts' consensus estimates of ($0.81) by $0.13. The business earned $1.01 million during the quarter, compared to the consensus estimate of $0.47 million. Chinook Therapeutics had a negative trailing twelve-month return on equity of 58.28% and a negative net margin of 4,199.93%.

What other stocks do shareholders of Chinook Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Chinook Therapeutics investors own include BioSyent (RX) and Continental Resources (CLR).

What is Chinook Therapeutics' stock symbol?

Chinook Therapeutics trades on the NASDAQ under the ticker symbol "KDNY."

Who are Chinook Therapeutics' major shareholders?

Chinook Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.94%), State Street Corp (4.05%), Alpine Associates Management Inc. (3.18%), Eventide Asset Management LLC (2.68%), Suvretta Capital Management LLC (2.43%) and Dimensional Fund Advisors LP (1.99%). Insiders that own company stock include Alan Glicklich, Andrew James King, Davis Jerel, Eric Bjerkholt, Eric Dobmeier, Mahesh Krishnan, Srinivas Akkaraju, Tom Frohlich, Versant Venture Capital Vii, L and William Mariner Greenman.
View institutional ownership trends
.

What is Chinook Therapeutics' stock price today?

One share of KDNY stock can currently be purchased for approximately $40.39.

How much money does Chinook Therapeutics make?

Chinook Therapeutics (NASDAQ:KDNY) has a market capitalization of $2.90 billion and generates $6.13 million in revenue each year. The company earns $-187,870,000.00 in net income (profit) each year or ($3.52) on an earnings per share basis.

How many employees does Chinook Therapeutics have?

The company employs 214 workers across the globe.

How can I contact Chinook Therapeutics?

Chinook Therapeutics' mailing address is 740 HEINZ AVENUE, BERKELEY CA, 94710. The official website for the company is chinooktx.com. The company can be reached via phone at (206) 485-7241 or via email at investors@aduro.com.

This page (NASDAQ:KDNY) was last updated on 9/23/2023 by MarketBeat.com Staff

My Account -